GlassScriptPhysician profile
John MD Draper
NPI 1174541817
$1,427.61
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $316 · 2021: $562 · 2022: $210.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $254.78 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $201.72 | 2019-2021 | |
| Novo Nordisk INC | $171.47 | 2019-2022 | |
| Abbvie INC. | $129.59 | 2021-2022 | |
| Allergan, INC. | $96.66 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.13 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $62.74 | 2019-2021 | |
| Pfizer INC. | $58.67 | 2019-2021 | |
| Amgen INC. | $55.32 | 2019-2022 | |
| Amarin Pharma, INC. | $30.84 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.38 | 2022 | |
| Lilly USA, LLC | $27.25 | 2021 | |
| Genentech USA, INC. | $24.23 | 2021 | |
| Ironshore Pharmaceuticals INC. | $23.75 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.90 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.57 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.23 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $17.42 | 2021 | |
| Hikma Pharmaceuticals USA | $16.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.98 | 2022 | |
| Glaxosmithkline, LLC. | $15.20 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.80 | 2022 | |
| Shire North American Group INC | $14.20 | 2019 | |
| Clarus Therapeutics INC. | $14.06 | 2021 | |
| Gilead Sciences, INC. | $13.30 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.70 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Draper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.